Advances in Lymphoma
Transcript: inMIND: Potential new standard of care
Dr Francine Foss
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, lenalidomide and rituximab has remained a standard for these patients. And some of the issues with this are that obviously not all patients respond and the progression-free survival may not be optimal. So the addition of a novel agent to this backbone I think was interesting given the alternative mechanism of action. Again, this is all a biologically-focused regimen. It's not a cytotoxic chemotherapy regimen. So there are certainly benefits for the patient from that point of view. What this study really demonstrated was I think, a meaningful improvement, a meaningful improvement in progression-free survival, and a trend toward perhaps an improvement in overall survival.
So I think that's what really makes this stand out in my mind is perhaps we can actually start moving the dial a little bit in patients with follicular lymphoma. Well, I think that's a very important aspect of this because to date, we really haven't understood the biology of that and how that would play out in the clinic. So I think this is giving us our first indication that that could be a successful thing that we might consider doing and combining perhaps with other agents as well, other targeted agents.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event